Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fate Therapeutics

1.25
+0.140012.61%
Post-market: 1.280.0300+2.40%19:56 EDT
Volume:5.76M
Turnover:7.40M
Market Cap:143.25M
PE:-0.76
High:1.39
Open:1.10
Low:1.10
Close:1.11
Loading ...

Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag

Zacks
·
15 Apr

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (Rmat) Designation From FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (Sle)

THOMSON REUTERS
·
14 Apr

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

GlobeNewswire
·
14 Apr

Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound?

Zacks
·
04 Apr

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
03 Apr

Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target

Simply Wall St.
·
08 Mar

Fate Therapeutics Inc. Faces Global Expansion Challenges Amid Political and Economic Uncertainties

TIPRANKS
·
07 Mar

Wedbush Remains a Hold on Fate Therapeutics (FATE)

TIPRANKS
·
07 Mar

Cautious Optimism: Hold Rating for Fate Therapeutics Amid Early-Stage Progress and Market Uncertainties

TIPRANKS
·
07 Mar

Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and Elicio Therapeutics (ELTX)

TIPRANKS
·
07 Mar

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE) and Stevanato Group (STVN)

TIPRANKS
·
06 Mar

Fate Therapeutics Price Target Maintained With a $5.00/Share by Wedbush

Dow Jones
·
06 Mar

Fate Therapeutics Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
06 Mar

FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus

Zacks
·
06 Mar

Stifel Nicolaus Sticks to Their Hold Rating for Fate Therapeutics (FATE)

TIPRANKS
·
06 Mar

Hold Rating for Fate Therapeutics Amid Early-Stage Pipeline Uncertainty and Cautious Cash Position

TIPRANKS
·
06 Mar

Fate Therapeutics price target lowered to $3 from $5 at Stifel

TIPRANKS
·
06 Mar

Barclays Keeps Their Buy Rating on Fate Therapeutics (FATE)

TIPRANKS
·
06 Mar

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE), Organon (OGN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
06 Mar

Cautious Outlook on Fate Therapeutics Amid FT819 Program Developments and Financial Uncertainties

TIPRANKS
·
06 Mar